As of April, 2021, India stood second in the global list of the highest incidence of Covid-19 cases, consequently drawing acute scrutiny and worldwide attention to the Indian healthcare framework. A very tangible fear of overburdening facilities and exhausting the supply of isolation beds and ventilators had forced India into a premature lockdown that has since crippled its economy. Covid-19 has revealed cracks in the healthcare structures of countries across the globe, and, in spite of the tremendous improvement in Indian healthcare over the years, India is still not equipped to cater to its overwhelming population of 1.3 billion people. Through an analysis of Indian Healthcare fundamentals, and its competitive factors, this paper seeks to examine and evaluate India’s position in its fight against Covid-19. This paper examines the Competition Commission of India’s Policy released in 2018, shedding light on the competitive issues faced by the Indian healthcare and pharmaceutical sector. A comparative analysis of the healthcare structures of China, Australia, European Union and the United States assists in critically assessing the response of the Indian competition authorities to the pandemic, and provides insight into establishing a more robust competition market for Indian healthcare that would invariably protect consumers.

Keywords: Competition Analysis, Covid-19 Healthcare, Indian Healthcare Infrastructure

 Download Full Paper